Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study
Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study. J Clin Oncol. 2008; 26(2):204-210.